Ocumed, eye drops 0.5% 10 ml

A nonselective beta-adrenoblocker for topical use in ophthalmology. It has no intrinsic sympathomimetic and membranostabilizing activity.

The drug reduces both normal and elevated intraocular pressure by reducing the formation of intraocular fluid. It does not influence the pupil size and accommodation.

The action of the drug is seen 20 minutes after injection into the conjunctival sac. The maximum decrease of intraocular pressure occurs within 1-2 hours and lasts for 24 hours.

Indications

– Increased intraocular pressure (ophthalmohypertension);

– Open-angle glaucoma;

– secondary glaucoma;

– For lowering intraocular pressure in closed angle glaucoma (as an adjunctive agent in combination with miotics);

– congenital glaucoma (in case other therapeutic measures are insufficient).

Active ingredient

Composition

Timolol (in maleate form) – 5 mg

How to take, the dosage

Adults and children over 10 years of age should be put in 1 drop (0.25% eye drops) into conjunctival sac of the affected eye 2 times a day, in case of insufficient effectiveness – 1 drop (0.5% eye drops) 2 times a day. If intraocular pressure is normalized, the maintenance dose is 1 drop (eye drops 0.25%) once daily.

Children under 10 years of age are prescribed 1 drop (eye drops 0.25%) 2 times daily.

The drug is intended for long-term continuous use.

The patient needs to be advised that only a physician can change the dose or temporarily discontinue the medication.

Interaction

The co-administration of Ocumed with eye drops containing epinephrine may cause dilation of the pupil.

The decrease in intraocular pressure is increased by concomitant use of eye drops containing epinephrine and pilocarpine. Two beta-adrenoblockers should not be put into the eyes.

Lowering of BP and slowing of heart rate may be increased when the drug is used together with slow calcium channel blockers, reserpine and other beta-adrenoblockers.

Simultaneous use with insulin or oral antidiabetic agents may lead to hypoglycemia.

Timolol increases the effect of peripheral muscle relaxants (it is necessary to cancel the drug 48 hours before the planned surgical intervention with general anesthesia).

Special Instructions

The patient should be advised to have regular intraocular pressure measurements and corneal examinations and to discontinue use and consult a physician if any side effects occur.

When wearing soft contact lenses, Ocumed Eye Drops should not be used as the preservative in these drops may deposit in the soft contact lenses and have an adverse effect on the eye tissue.

Hard contact lenses should be removed prior to putting the product in and reinserted after 15 minutes.

Patients changing to Ocumed may need refraction correction (once the effects of previous myotics have subsided).

Ocumed should be discontinued 48 hours before surgical intervention with general anesthesia.

Ocumed should not be used simultaneously with antipsychotic (neuroleptics) and anxiolytic (tranquilizers) drugs.

Alcohol consumption is not recommended during the use of the drug (a sharp decrease in BP may occur).

Pediatric use

There is not enough experience in using the drug in children; therefore, the drug can only be prescribed if the expected benefits of therapy outweigh the potential risk of side effects.

Impact on driving and operating ability

In the immediate after use of the drug there may be decrease in visual acuity and delayed psychomotor reactions, which may decrease the ability to perform potentially dangerous activities requiring increased attention (especially with concomitant use of alcohol).

Contraindications

– bronchial asthma or other severe chronic obstructive airways disease;

– sinus bradycardia;

– AV blockade of II and III degree;

– acute heart failure;

– severe chronic heart failure (functional class III and IV according to NYHA classification);

– cardiogenic shock;

– allergic reactions with generalized skin rash;

– atrophic rhinitis;

– dystrophic corneal diseases;

– period of newborn;

– hypersensitivity to the components of the drug.

The drug is administered with caution in patients with pulmonary insufficiency, pulmonary emphysema, severe cerebrovascular insufficiency, heart failure (functional class I and II according to NYHA classification), sinoatrial blockade, arterial hypertension, diabetes, hypoglycemia, thyrotoxicosis, myasthenia gravis, Reye syndrome, when other beta-adrenoblockers are prescribed simultaneously, and also in children.

Side effects

Visually: irritation and hyperemia of the conjunctiva, eyelid skin, burning and itching in the eyes, lacrimation or reduced lacrimation, photophobia, corneal epithelial edema, pitting superficial keratopathy, corneal hypoesthesia, diplopia, ptosis, dry eyes, transient visual acuity failure, blepharitis, conjunctivitis, keratitis. During surgical interventions for glaucoma a detachment of the vasculature of the eye may develop in the postoperative period.

Cardiovascular system disorders: chest pain, heart failure, bradycardia, bradyarrhythmia, decreased blood pressure, collapse, AV-blockade, cardiac arrest, transient cerebral circulatory disorders.

Respiratory system: rhinitis, dyspnea, bronchospasm, pulmonary failure.

CNS and peripheral nervous system disorders: headache, dizziness, weakness, depression, paresthesias, myasthenia, somnolence, hallucinations, tinnitus, slowed psychomotor reaction rate.

Digestive system disorders: nausea, vomiting, diarrhea.

Allergic reactions: urticaria, eczema.

Other: nasal bleeding, decreased potency, alopecia.

Overdose

Symptoms: due to local absorption systemic effects typical for beta-adrenoblockers (dizziness, headache, arrhythmia, bradycardia, bronchospasm, nausea, vomiting) may develop.

Treatment: immediately flush eyes with water or saline. Symptomatic therapy is carried out.

Similarities